Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Alerts
5.29.26
Insights from the 2026 FTC Workshop on Last-Minute Antitrust Remedy Proposals
On May 20, 2026, the Federal Trade Commission (FTC) hosted “Eleventh-Hour Antitrust Remedy Proposals and Litigating the Fix” Workshop, which provided meaningful insight into how the agency is likely to approach merger remedies under its current leadership. Chairman Andrew Ferguson delivered the opening remarks, and Commissioner Mark Meador gave the closing remarks.
Client Highlights
4.14.26
Wilson Sonsini Advises Special Committee of the Board in Globalstar's Acquisition by Amazon
On April 14, 2026, Amazon and Globalstar announced they have entered into a definitive merger agreement under which Amazon will acquire Globalstar, a leading mobile satellite services (MSS) operator, a pioneer in non-geostationary orbit (NGSO) satellites and D2D technology, and a provider of critical and emergency communications to customers around the world. Wilson Sonsini Goodrich & Rosati is representing the special committee of Globalstar’s board of directors on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Insilico on Global R&D Collaboration with Lilly
On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
3.30.26
Wilson Sonsini Advises Octopus Energy on Majority Stake Acquisition of Uplight
On March 24, 2026, Octopus Energy Group, a global clean energy and technology business driving the affordable, green energy system of the future, will cement its expansion in the U.S. by acquiring a majority stake in Uplight, a leading provider of customer engagement and flexibility management solutions that rapidly transform customer participation into dependable grid capacity. The deal is made in partnership with Schneider Electric, a global energy technology leader trusted by utilities worldwide, which will remain as a significant minority partner. The transaction is subject to customary regulatory approvals and is expected to complete later this year. Wilson Sonsini Goodrich & Rosati advised Octopus Energy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.23.26
Wilson Sonsini Advises Brex on $5.15 Billion Acquisition by Capital One
On January 22, 2026, Capital One announced that it has entered into a definitive agreement to acquire Brex, in a combination of stock and cash transaction valued at $5.15 billion. Brex is a modern, AI-native software platform offering intelligent finance solutions that make it easy for businesses to issue corporate cards, automate expense management, and make secure, real-time payments. The transaction is expected to close in the middle of 2026, subject to customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Brex on the transaction.
News Articles
1.16.26
Firm Attorneys Named to 2026 Lawdragon 500 Leading Global Antitrust & Competition Lawyers
On January 16, 2026, 15 Wilson Sonsini attorneys were selected for inclusion in Lawdragon’s “500 Leading Antitrust & Global Competition Lawyers” guide. The lawyers featured are recognized for navigating global antitrust regulatory regimes, representing clients in massive competition contests, and navigating frameworks of countries and markets globally.
Client Highlights
1.16.26
Wilson Sonsini Advises Battle Road Digital on Acquisition by Onebrief
On January 13, 2026, Onebrief, the operating system for modern command, announced that it has acquired Battle Road Digital, a leading defense innovation company applying best-in-class gaming technology to defense and national security challenges. Wilson Sonsini Goodrich & Rosati advised Battle Road Digital on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.